Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
- PMID: 35643092
- DOI: 10.1016/S1474-4422(22)00168-5
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Abstract
Background: Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease that is closely linked both spatially and temporally to emergence of neurodegeneration and manifestation of clinical symptoms. There is an urgent need for accurate PET, CSF, and plasma biomarkers of tau pathology to improve the diagnostic process in clinical practice and the selection of participants and monitoring of treatment effects in trials.
Recent developments: Innovative second-generation tau-PET tracers with high affinity and selectivity to tau pathology in Alzheimer's disease have enabled detection of tau pathology in medial temporal lobe subregions that are affected in the earliest disease stages. Furthermore, novel but common tau spreading subtypes have been discovered using tau-PET, suggesting much greater interindividual differences in the distribution of tau pathology across the brain than previously assumed. In the CSF biomarker field, novel phosphorylated tau (p-tau) assays have been introduced that better reflect tau tangle load than established CSF biomarkers of tau pathology. The advent of cost-effective and accessible blood-based biomarkers for tau pathophysiology (ie, p-tau181, p-tau217, and p-tau231) might transform the Alzheimer's disease field, as these biomarkers correlate with post-mortem Alzheimer's disease pathology, differentiate Alzheimer's disease from other types of dementia, and predict future progression from normal cognition and mild cognitive impairment to Alzheimer's disease. In controlled investigational settings, improvements in tau-PET and biofluid p-tau markers have led to earlier disease detection, more accurate diagnostic methods, and refinement of prognosis. The anti-tau therapy landscape is rapidly evolving, with multiple ongoing phase 1 and 2 trials of post-translational modification of tau, tau immunotherapy, tau aggregation inhibitors, and targeting production of tau and reduction of intracellular tau levels. Neuroimaging and biofluid tau markers hold potential for optimising such clinical trials by augmenting participant selection, providing evidence of target engagement, and monitoring treatment efficacy. WHERE NEXT?: Major challenges to overcome are the high cost of tau-PET, partial sensitivity to detect early-stage Alzheimer's disease pathology, and off-target tracer binding. Prospective validation studies of biofluid p-tau markers are needed, and assay-related preanalytical and analytical factors need further refinement. Future studies should focus on demonstrating the diagnostic and prognostic accuracy of tau biomarkers-blood-based markers in particular-in non-tertiary settings, such as primary care, which is characterised by a diverse population with medical comorbidities. Large-scale head-to-head studies are needed across different stages of Alzheimer's disease to determine which tau biomarker is optimal in various clinical scenarios, such as early diagnosis, differential diagnosis, and prognosis, and for aspects of clinical trial design, such as proving target engagement, optimising participant selection, and refining monitoring of treatment effects.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests OH has acquired research support for Lund University from Avid Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy and speaker fees from Roche, Genentech, Siemens, Biogen, Alzpath, and Cerveau. RO and RVDK declare no competing interests.
Similar articles
-
Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications.Mol Neurodegener. 2023 Mar 16;18(1):18. doi: 10.1186/s13024-023-00605-8. Mol Neurodegener. 2023. PMID: 36927491 Free PMC article. Review.
-
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.Lancet Neurol. 2021 Sep;20(9):739-752. doi: 10.1016/S1474-4422(21)00214-3. Lancet Neurol. 2021. PMID: 34418401 Free PMC article.
-
Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.Acta Neuropathol. 2021 May;141(5):709-724. doi: 10.1007/s00401-021-02275-6. Epub 2021 Feb 14. Acta Neuropathol. 2021. PMID: 33585983 Free PMC article.
-
Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.Brain. 2021 Feb 12;144(1):325-339. doi: 10.1093/brain/awaa399. Brain. 2021. PMID: 33257949 Free PMC article.
-
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Alzheimers Dement. 2008. PMID: 18631949 Review.
Cited by
-
AdipoRon Ameliorates Synaptic Dysfunction and Inhibits tau Hyperphosphorylation through the AdipoR/AMPK/mTOR Pathway in T2DM Mice.Neurochem Res. 2024 Aug;49(8):2075-2086. doi: 10.1007/s11064-024-04162-4. Epub 2024 May 31. Neurochem Res. 2024. PMID: 38819697
-
Alcohol Use Disorder and Dementia: A Review.Alcohol Res. 2024 May 23;44(1):03. doi: 10.35946/arcr.v44.1.03. eCollection 2024. Alcohol Res. 2024. PMID: 38812709 Free PMC article. Review.
-
Informational Analysis and Prediction of Obsessive-Compulsive Disorder Pathogenesis.Psychiatry Investig. 2024 May;21(5):464-474. doi: 10.30773/pi.2023.0149. Epub 2024 May 23. Psychiatry Investig. 2024. PMID: 38810995 Free PMC article.
-
Photobiomodulation in experimental models of Alzheimer's disease: state-of-the-art and translational perspectives.Alzheimers Res Ther. 2024 May 21;16(1):114. doi: 10.1186/s13195-024-01484-x. Alzheimers Res Ther. 2024. PMID: 38773642 Free PMC article. Review.
-
Evaluating p-tau217 and p-tau231 as Biomarkers for Early Diagnosis and Differentiation of Alzheimer's Disease: A Narrative Review.Biomedicines. 2024 Apr 3;12(4):786. doi: 10.3390/biomedicines12040786. Biomedicines. 2024. PMID: 38672142 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical